Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

Selvaggi, G.Wakelee, H. A.Mok, T.Wu, Y. -L.Reck, M.Chiappori, A.Cicin, I.2024-06-122024-06-1220201556-08641556-1380https://hdl.handle.net/20.500.14551/18272[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessALK Plus NSCLCEnsartinibCrizotinibPhase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3Conference Object1510E41E42Q1WOS:000569266100003